Protara's 55% CR Rate in BCG-Naïve NMIBC: A Step, Not a Leap

What happened

Protara reported 12-month Phase 2 data for TARA-002 in BCG-naïve NMIBC, showing a 55% complete response rate with favorable safety. While positive, this single-arm, early-stage result comes from a less challenging cohort and does not address the pivotal BCG-unresponsive group due by end-2025. The DeepValue report had previously rated the stock a 'WAIT' given its pre-revenue status and binary trial outcomes. This data reduces some uncertainty but does not change the fundamental risk/reward calculus. The stock's recent run-up may have already priced in this catalyst, leaving the next binary readout as the true inflection point.

Implication

Protara's Phase 2 data in BCG-naïve patients is a positive signal that appears to meet expectations, but it does not provide clarity on the harder-to-treat BCG-unresponsive population, which is the focus of the registration-directed cohort. The stock has already appreciated significantly, and this news may have been partially anticipated, limiting further upside from this catalyst alone. For investors, the thesis remains dependent on the end-2025 pivotal data; until then, the risk/reward is finely balanced. We see this as a modest de-risking but not a reason to upgrade the stance from cautious to bullish. Continued monitoring of the unresponsive cohort and cash runway is essential.

Thesis delta

The updated data slightly de-risks TARA-002 in the BCG-naïve setting, but the main investment thesis hinges on the BCG-unresponsive cohort. The risk/reward remains finely balanced, and we maintain a cautious 'WAIT' stance until the pivotal readout provides clearer direction.